Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30121% above fair value

$23.04−0.92 (-3.84%)

Close on Nov 13, 2026Market cap $6.51BP/E –Yield –

Caris Life Sciences gross margin

Gross margin is gross profit as a percentage of revenue.

Caris Life Sciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Caris Life Sciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CAI.

Revenue growth61.5% · median 27.5%

Operating margin13.4% · median -8.2%

Net margin9.2% · median -5.9%

Advertisement
300 × 250

See a number that looks wrong?